Differential response to aminergic stimuli and biological behavior of growth hormone secreting pituitary adenomas.
Growth hormone (GH) serum levels in response to the administration of aminergic drugs and thyroliberine (TRH) were determined in a group of 34 acromegalics. Administration of bromocriptine (10 mg single oral dose) was followed by a decrease in GH below 60% control values in 35% of the cases. Administration of diazepam (10 mg single oral dose) to those cases not responding to bromocriptine induced a decrease in GH in 58% of the cases and an increase in GH in 42%. Administration of cyproheptadine (24 mg/day for one month) to those cases not responding to bromocriptine or with increased GH after the administration of diazepam, decreased GH in 75%, while increased GH in 25% of the cases. TRH 200 micrograms single I.V. dose induced increase of 128% GH basal level in 65% of cases (TRH positive) which correlated with more benign clinical course, decreased GH levels in response to bromocriptine, increased PRL levels, PRL-GH mixed secreting adenomas in immunohistochemistry studies, presence of granulated cells in electron microscopy studies and normalization of GH in the majority of surgically treated cases. By contrast, TRH negative cells correlated with aggressive tumor growth, lack of response to bromocriptine, normal PRL levels, pure GH secreting adenomas by immunohistochemistry, poorly granulated cells and lack of response to surgical treatment. Results suggest that there is more than one type of acromegaly that might be distinguished by the aminergic control on GH secretion.
Fanghanel
G
G
Hypothalamus-Hypophysis Clinic, Hospital General de Mexico, Mexico, D.F.
Larraza
O
O
Villalobos
M
M
Fanghanel
L
L
Velasco
M
M
Velasco
F
F
D000172:Acromegaly / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D000236:Adenoma / Q000097:blood / Q000188:drug therapy / Q000378:metabolism* / Q000648:ultrastructure; D000293:Adolescent; D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use*; D003533:Cyproheptadine / Q000627:therapeutic use*; D003975:Diazepam / Q000627:therapeutic use*; D005260:Female; D013006:Growth Hormone / Q000097:blood / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000097:blood / Q000188:drug therapy / Q000378:metabolism* / Q000648:ultrastructure; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology*
D003533:Cyproheptadine; D001971:Bromocriptine; D013973:Thyrotropin-Releasing Hormone; D013006:Growth Hormone; D003975:Diazepam